Ligand Pharmaceuticals 

$0.045000
46
-$0.00-5.76% 19:23 Today

Statistics

Day High
0.045
Day Low
0.045
52W High
0.045
52W Low
0.045
Volume
100
Avg. Volume
-
Mkt Cap
897,345
P/E Ratio
-
Dividend Yield
9.07%
Dividend
0

Upcoming

Dividends

9.07%Dividend Yield
Jul 26
$0.00
Jan 26
$0.00
Jul 25
$0.05
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
329.88%

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
1.19
1.82
2.46
3.09
Expected EPS
1.99
Actual EPS
N/A

Financials

46.42%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
536.17MRevenue
248.91MNet Income

Analyst Ratings

270.80Average Price Target
The highest estimate is 289.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGNYZ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Ligand Pharmaceuticals Incorporated functions as a global biopharmaceutical entity, concentrating on the advancement and licensing of pharmaceutical assets. Its diverse portfolio includes commercial products targeting a wide array of serious health conditions. Key therapeutic offerings comprise Kyprolis and Evomela for the treatment of multiple myeloma, alongside Rylaze, an asparaginase formulation designed for both adult and pediatric patients battling acute lymphoblastic leukemia or lymphoblastic lymphoma. The company also provides Filspari, a dual endothelin and angiotensin II receptor antagonist, currently being developed for specific rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy. Further extending its reach, Ligand's portfolio features a teriparatide injection product for osteoporosis management. In the vaccine space, Vaxneuvance aims to prevent invasive disease caused by Streptococcus pneumoniae serotypes, while Pneumosil offers a pneumococcal conjugate vaccine primarily for children. A notable advancement is TZIELD, a CD3-directed antibody indicated to postpone the progression to Stage 3 type 1 diabetes in adults and children aged eight years and older who have Stage 2 T1D. Many of Ligand's solutions leverage its proprietary Captisol technology, enhancing drug formulations. Examples include Nexterone (a Captisol-enabled amiodarone), Zulresso (a Captisol-enabled brexanolone for postpartum depression), and Veklury, an antiviral treatment for moderate or severe COVID-19. The Captisol platform also supports Noxafil-IV, an IV formulation of posaconazole. Additional products in their repertoire address various indications such as post-menopausal symptoms (Duavee), autoimmune diseases (Exemptia), breast cancer (Vivitra), and other conditions through Bryxta and Zybev. Beyond its licensed therapies, Ligand also directly markets its Captisol materials. The company fosters strategic alliances, licenses, and business relationships with prominent pharmaceutical firms, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand Pharmaceuticals Incorporated, founded in 1987, maintains its headquarters in Jupiter, Florida.
Show more...
CEO
Mr. Todd C. Davis Ph.D.
Employees
68
Country
United States
ISIN
US53220K1997

Listings

0 Comments

Share your thoughts

FAQ

What is Ligand Pharmaceuticals stock price today?
The current price of LGNYZ is $0.05 USD — it has decreased by -5.76% in the past 24 hours. Watch Ligand Pharmaceuticals stock price performance more closely on the chart.
What is Ligand Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ligand Pharmaceuticals stocks are traded under the ticker LGNYZ.
What is Ligand Pharmaceuticals market cap?
Today Ligand Pharmaceuticals has the market capitalization of 897,345
When is the next Ligand Pharmaceuticals earnings date?
Ligand Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Ligand Pharmaceuticals earnings last quarter?
LGNYZ earnings for the last quarter are 1.63 USD per share, whereas the estimation was 1.82 USD resulting in a -10.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ligand Pharmaceuticals revenue for the last year?
Ligand Pharmaceuticals revenue for the last year amounts to 536.17M USD.
What is Ligand Pharmaceuticals net income for the last year?
LGNYZ net income for the last year is 248.91M USD.
Does Ligand Pharmaceuticals pay dividends?
Yes, LGNYZ dividends are paid semi-annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 9.07%.
How many employees does Ligand Pharmaceuticals have?
As of June 24, 2026, the company has 68 employees.
In which sector is Ligand Pharmaceuticals located?
Ligand Pharmaceuticals operates in the Other sector.
When did Ligand Pharmaceuticals complete a stock split?
The last stock split for Ligand Pharmaceuticals was on November 19, 2010 with a ratio of 1:6.
Where is Ligand Pharmaceuticals headquartered?
Ligand Pharmaceuticals is headquartered in Jupiter, United States.